PHA Europe, the European Pulmonary Hypertension Association, is celebrating this year’s World Pulmonary Hypertension Day with a webinar on non pulmonary arterial hypertension forms of pulmonary hypertension, featuring world renowned expert expert Ardeschir Ghofrani as keynote speaker. May 5, 2024 – 16:00 CET Link: https://belaircenter.info/
April 28 is ESOT – European Society for Organ Transplantation Action Day. ESOT is calling for enhanced cooperation among EU member states to empower transplant centres in delivering consistent, high-quality transplantation service ahead of the EU elections. ESOT is looking to drive the following 5 actions in the European Parliament between 2024 and 2029: Read
Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,
The Spanish Foundation for Pulmonary Hypertension, Fundación Contra la Hipertensión Pulmonar, has been selected as winner of one of the prizes of the “Inocente Foundation” for its project on “Non-invasive Remote Monitoring for children with Pulmonary Hypertension”, which will be carried out at the Ramón y Cajal University Hospital.
United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the
Dr. Joanna Pepke-Zaba, renowned consultant respiratory physician at Royal Papworth Hospital, recently received a prestigious European Respiratory Society (ERS) lifetime achievement award, marking another milestone in her illustrious career. In an interview with Saša Janković, recently published on March 18, 2024 on “Hospital Health Care Europe”, Dr. Pepke-Zaba discusses her dedication to advancing research and
The Annual General Assembly of the French Pulmonary Hypertension Association HTaPFrance is taking place in Paris on Saturday the 6th of April 2024 in Paris. The morning program is dedicated to the presentation of the annual report of activities, vote on financial report and approval of new members of the Board. The afternoon program features
The US Food and Drug Administration has approved sotatercept, Merck‘s new drug for pulmonary arterial hypertension. It’s commercial name is Winrevair. Read more on the FDA website at this link Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It was evaluated as an add-on to stable background therapy for the treatment of pulmonary
The Alliance for Pulmonary Hypertension is very honoured to present its Scientific Committee, featuring some of the world’s most renowned experts in the field of pulmonary hypertension. The Scientific Committee will play a pivotal role in supporting the Alliance’s mission to share knowledge and expertise about pulmonary hypertension via its Pulmonary Hypertension Knowledge Sharing Platform.
The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the
The first John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held in London, UK, 2006 to honour the memory of Sir John Vane, the founder of the William Harvey Research Institute and Nobel prize Laureate for his discovery of prostacyclin and its analogues (see also our article at this link). It
Delays to diagnosis in pulmonary arterial hypertension still persist today, despite the substantial progress made in the field. This ongoing issue continues to pose a significant challenge, highlighting the need for continued efforts to improve early detection and intervention strategies. Delays in diagnosis not only prolong patient suffering but also lead to missed opportunities for
The BEL AIR CENTER is a virtual conference center, divided into several “rooms” where visitors can find and view presentations from leading pulmonary hypertension experts and from PHA Europe’s industry partners, patient association information booths, an art gallery with works by patients and health care professionals, and a networking café. Prof. Marc Humbert, Director of
The 7th edition of the World Symposium on Pulmonary Hypertension is being held on June 29-30/July 1, 2024, in Barcelona, Spain. The WSPH is the most important scientific event in the field of pulmonary hypertension. It has been convened every five years since the Evian edition in 1998 (including Venice 2003, Dana Point 2008, Nice
The International Classification of Diseases (ICD) is a medical coding system crafted by the World Health Organization (WHO). It serves as the primary foundation for health recording and disease statistics across various levels of care, including primary, secondary, and tertiary care settings, as well as on death certificates to determine causes of mortality. These meticulously
Cereno Scientific announced on January 31, 2024 that it has received approval from the US Food and Drug Administration (FDA) for expanded access to the investigational drug CS1 in the ongoing Phase II trial for pulmonary arterial hypertension (PAH). This program allows patients who completed the Phase II to continue CS1 therapy. Positive outcomes from
“EXPOSURE” (EUPAS19085) is an observational study describing the characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension initiating a new specific therapy in Europe/Canada. In total, 1.944 patients with follow-up information were included. Most study patients were female with WHO functional class II/III symptoms and idiopathic or connective tissue disorder-associated pulmonary arterial hypertension.
The authors of this article, titled “How your patient is really feeling: the emotional hinterland of a cardiac diagnosis“, published on the European Heart Journal on January 8, 2024, focus on the impact of receiving and living with a cardiac disease diagnosis, and in particular to the psychosocial aspects, which, they say, continue to be underrepresented in
Prof. Adam Torbicki’s presentation is titled “Access to care for pulmonary arterial hypertension and chronic thromboembolic pulmponary hypertension”. It can be viewed at this link on Vimeo (you need to register on Vimeo to see it) Prof. Jean-Luc Vachiéry’s presentation is titled “Drug development and clinical trials“. It can be viewed at this link on
It was a great honour to be invited to speak at the ERN-LUNG webinar on quality indicators for adult pulmonary arterial hypertension care, which took place on December 8, 2023, where I was asked to explain why these are important from a patient perspective. The webinar referenced an article in the European Journal of Heart
